Click on image to view larger version.

Figure 5 Cumulative rate of primary events (all strokes and systemic embolic events) according to assigned treatment and intention-to-treat in the Stroke Prevention with an ORal Thrombin Inhibitor in Atrial Fibrillation (SPORTIF)-III trial (47).